Ziopharm Oncology Shares Fall as Cancer Therapy Trial Misses Primary Endpoint

Published March 26, 2013

Ziopharm Oncology shares fall as cancer therapy trial misses primary endpoint

Filed under: drug treatment programs maryland

The biopharmaceutical company said that the drug, for the treatment of metastatic soft tissue sarcoma in the first-line setting, did not meet its primary endpoint of progression-free survival during a phase 3 trial, but that the study's independent …
Read more on Proactive Investors USA & Canada

Health Care Reform Update March 25, 2013

Filed under: drug treatment programs maryland

Avastin is used to treat macular degeneration, although there are reports of eye infections in five patients who used the drug. Clinical Specialties recalled 40 lots of Avastin sent to … The letter urges CMS to delay any further cuts or program …
Read more on The National Law Review

Omeros Announces Successful Completion Of PDE10 Phase 1 Multiple …

Filed under: drug treatment programs maryland

These results show that OMS824, at well-tolerated doses, achieves concentrations that are anticipated to effectively inhibit PDE10 and support continuing development for the treatment of Huntington's disease, schizophrenia and other central nervous …
Read more on Daily Markets (press release)